POMDOCTOR Ltd

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, ONC has a market cap of 31.3B. Regarding current trading prices, POM is priced at $0.11, while ONC trades at $293.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas ONC's P/E ratio is 66.50. In terms of profitability, POM's ROE is +0.07%, compared to ONC's ROE of +0.12%. Regarding short-term risk, POM is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check ONC's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, POM is priced at $0.11, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas WBA's P/E ratio is -1.64. In terms of profitability, POM's ROE is +0.07%, compared to WBA's ROE of -0.39%. Regarding short-term risk, POM is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check WBA's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, POM is priced at $0.11, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas HROWL's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, POM is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check HROWL's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, POM is priced at $0.11, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas HROWM's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, POM is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check HROWM's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, AVLN has a market cap of 1.2B. Regarding current trading prices, POM is priced at $0.11, while AVLN trades at $29.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas AVLN's P/E ratio is -14.63. In terms of profitability, POM's ROE is +0.07%, compared to AVLN's ROE of N/A. Regarding short-term risk, POM is more volatile compared to AVLN. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check AVLN's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, CGEM has a market cap of 966.7M. Regarding current trading prices, POM is priced at $0.11, while CGEM trades at $15.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas CGEM's P/E ratio is -4.67. In terms of profitability, POM's ROE is +0.07%, compared to CGEM's ROE of -0.51%. Regarding short-term risk, POM is more volatile compared to CGEM. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check CGEM's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, ATAI has a market cap of 757.3M. Regarding current trading prices, POM is priced at $0.11, while ATAI trades at $4.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas ATAI's P/E ratio is -1.41. In terms of profitability, POM's ROE is +0.07%, compared to ATAI's ROE of -3.66%. Regarding short-term risk, POM is more volatile compared to ATAI. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check ATAI's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, HITI has a market cap of 211.8M. Regarding current trading prices, POM is priced at $0.11, while HITI trades at $2.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas HITI's P/E ratio is -5.74. In terms of profitability, POM's ROE is +0.07%, compared to HITI's ROE of -0.41%. Regarding short-term risk, POM is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check HITI's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, LFMD has a market cap of 209.4M. Regarding current trading prices, POM is priced at $0.11, while LFMD trades at $4.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas LFMD's P/E ratio is -9.84. In terms of profitability, POM's ROE is +0.07%, compared to LFMD's ROE of -1.72%. Regarding short-term risk, POM is more volatile compared to LFMD. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check LFMD's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, LFMDP has a market cap of 163M. Regarding current trading prices, POM is priced at $0.11, while LFMDP trades at $23.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas LFMDP's P/E ratio is -10.59. In terms of profitability, POM's ROE is +0.07%, compared to LFMDP's ROE of -1.72%. Regarding short-term risk, POM is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check LFMDP's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, POM is priced at $0.11, while LFLY trades at $37.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas LFLY's P/E ratio is -0.04. In terms of profitability, POM's ROE is +0.07%, compared to LFLY's ROE of +0.17%. Regarding short-term risk, POM is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for POM.Check LFLY's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, YI has a market cap of 50.5M. Regarding current trading prices, POM is priced at $0.11, while YI trades at $5.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas YI's P/E ratio is -5.18. In terms of profitability, POM's ROE is +0.07%, compared to YI's ROE of +0.08%. Regarding short-term risk, POM is more volatile compared to YI. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check YI's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, PETS has a market cap of 47.7M. Regarding current trading prices, POM is priced at $0.11, while PETS trades at $2.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas PETS's P/E ratio is -0.72. In terms of profitability, POM's ROE is +0.07%, compared to PETS's ROE of -1.22%. Regarding short-term risk, POM is more volatile compared to PETS. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check PETS's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, SDEV has a market cap of 44.7M. Regarding current trading prices, POM is priced at $0.11, while SDEV trades at $1.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas SDEV's P/E ratio is -0.29. In terms of profitability, POM's ROE is +0.07%, compared to SDEV's ROE of +12.37%. Regarding short-term risk, POM is more volatile compared to SDEV. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check SDEV's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, POM is priced at $0.11, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas RAD's P/E ratio is -0.05. In terms of profitability, POM's ROE is +0.07%, compared to RAD's ROE of +2.76%. Regarding short-term risk, POM is more volatile compared to RAD. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check RAD's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, RNTX has a market cap of 29.4M. Regarding current trading prices, POM is priced at $0.11, while RNTX trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas RNTX's P/E ratio is -0.54. In terms of profitability, POM's ROE is +0.07%, compared to RNTX's ROE of -2.58%. Regarding short-term risk, POM is more volatile compared to RNTX. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check RNTX's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, KYNB has a market cap of 27.6M. Regarding current trading prices, POM is priced at $0.11, while KYNB trades at $6.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas KYNB's P/E ratio is -0.49. In terms of profitability, POM's ROE is +0.07%, compared to KYNB's ROE of -1.82%. Regarding short-term risk, POM is more volatile compared to KYNB. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check KYNB's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, NEUP has a market cap of 25.5M. Regarding current trading prices, POM is priced at $0.11, while NEUP trades at $4.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas NEUP's P/E ratio is -6.86. In terms of profitability, POM's ROE is +0.07%, compared to NEUP's ROE of -15.59%. Regarding short-term risk, POM is more volatile compared to NEUP. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check NEUP's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, POM is priced at $0.11, while MEDS trades at $7.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas MEDS's P/E ratio is -0.31. In terms of profitability, POM's ROE is +0.07%, compared to MEDS's ROE of -2.36%. Regarding short-term risk, POM is more volatile compared to MEDS. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check MEDS's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, POM is priced at $0.11, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas CJJD's P/E ratio is -0.46. In terms of profitability, POM's ROE is +0.07%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, POM is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check CJJD's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, MSLE has a market cap of 9M. Regarding current trading prices, POM is priced at $0.11, while MSLE trades at $7.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas MSLE's P/E ratio is -4.27. In terms of profitability, POM's ROE is +0.07%, compared to MSLE's ROE of -0.52%. Regarding short-term risk, POM is more volatile compared to MSLE. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check MSLE's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, POM is priced at $0.11, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas SSY's P/E ratio is -2.86. In terms of profitability, POM's ROE is +0.07%, compared to SSY's ROE of -0.15%. Regarding short-term risk, POM is more volatile compared to SSY. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check SSY's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, AIXC has a market cap of 6.6M. Regarding current trading prices, POM is priced at $0.11, while AIXC trades at $1.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas AIXC's P/E ratio is -0.15. In terms of profitability, POM's ROE is +0.07%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, POM is more volatile compared to AIXC. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check AIXC's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, HKPD has a market cap of 5.8M. Regarding current trading prices, POM is priced at $0.11, while HKPD trades at $0.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas HKPD's P/E ratio is -8.84. In terms of profitability, POM's ROE is +0.07%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, POM is more volatile compared to HKPD. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check HKPD's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, POM is priced at $0.11, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas MDVL's P/E ratio is -0.05. In terms of profitability, POM's ROE is +0.07%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, POM is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for POM.Check MDVL's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, POM is priced at $0.11, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas ATNFW's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to ATNFW's ROE of -0.91%. Regarding short-term risk, POM is more volatile compared to ATNFW. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check ATNFW's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, POM is priced at $0.11, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas BGMSP's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to BGMSP's ROE of -2.95%. Regarding short-term risk, POM is more volatile compared to BGMSP. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check BGMSP's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, NVOH has a market cap of 2.2M. Regarding current trading prices, POM is priced at $0.11, while NVOH trades at $24.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas NVOH's P/E ratio is 12.88. In terms of profitability, POM's ROE is +0.07%, compared to NVOH's ROE of +0.00%. Regarding short-term risk, POM is more volatile compared to NVOH. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check NVOH's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, BGMS has a market cap of 2.2M. Regarding current trading prices, POM is priced at $0.11, while BGMS trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas BGMS's P/E ratio is -0.15. In terms of profitability, POM's ROE is +0.07%, compared to BGMS's ROE of -0.58%. Regarding short-term risk, POM is more volatile compared to BGMS. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check BGMS's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, POM is priced at $0.11, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas AZNH's P/E ratio is 38.35. In terms of profitability, POM's ROE is +0.07%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, POM is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check AZNH's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, POM is priced at $0.11, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, POM's ROE is +0.07%, compared to LFLYW's ROE of +0.17%. Regarding short-term risk, POM is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check LFLYW's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, POM is priced at $0.11, while BIMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas BIMI's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, POM is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check BIMI's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, POM is priced at $0.11, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas SHPG's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, POM is more volatile compared to SHPG. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check SHPG's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, POM is priced at $0.11, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas ESRX's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, POM is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check ESRX's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, CPD has a market cap of 0. Regarding current trading prices, POM is priced at $0.11, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas CPD's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to CPD's ROE of N/A. Regarding short-term risk, POM is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check CPD's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, POM is priced at $0.11, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas IPXL's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, POM is more volatile compared to IPXL. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check IPXL's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, OREX has a market cap of 0. Regarding current trading prices, POM is priced at $0.11, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas OREX's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to OREX's ROE of -0.54%. Regarding short-term risk, POM is less volatile compared to OREX. This indicates potentially lower risk in terms of short-term price fluctuations for POM.Check OREX's competition here

POM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, POM stands at 12.1M. In comparison, POZN has a market cap of 0. Regarding current trading prices, POM is priced at $0.11, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

POM currently has a P/E ratio of -1.89, whereas POZN's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.07%, compared to POZN's ROE of +0.61%. Regarding short-term risk, POM is more volatile compared to POZN. This indicates potentially higher risk in terms of short-term price fluctuations for POM.Check POZN's competition here